KR920700034A - 5-ht₃수용체 길항제의 치료용도 - Google Patents

5-ht₃수용체 길항제의 치료용도

Info

Publication number
KR920700034A
KR920700034A KR1019900702651A KR900702651A KR920700034A KR 920700034 A KR920700034 A KR 920700034A KR 1019900702651 A KR1019900702651 A KR 1019900702651A KR 900702651 A KR900702651 A KR 900702651A KR 920700034 A KR920700034 A KR 920700034A
Authority
KR
South Korea
Prior art keywords
methyl
imidazol
propanone
oct
carboxyamide
Prior art date
Application number
KR1019900702651A
Other languages
English (en)
Inventor
알베르토 아즈코나
Original Assignee
예안 크라메르·한스 루돌프 하우스
산도즈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898909147A external-priority patent/GB8909147D0/en
Priority claimed from GB898916602A external-priority patent/GB8916602D0/en
Application filed by 예안 크라메르·한스 루돌프 하우스, 산도즈 아게 filed Critical 예안 크라메르·한스 루돌프 하우스
Publication of KR920700034A publication Critical patent/KR920700034A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Abstract

내용 없음

Description

5-HT3수용체 길항제의 치료용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 5-HT3수용체 길항제의 치료 유효량을 상기 치료가 요구되는 대상에게 투여하는 것을 포함하는 공포성 질환 및/또는 공간 공포증이나 강박성 신경증 질환에 걸린 또는 걸리기 쉬운 대상을 치료하는 방법.
  2. 공포성 질환 및/또는 공간 공포증이나 강박성 신경증 질환을 치료하기 위한 5-HT3수용체 길항제의 용도.
  3. 활성 성분으로 5-HT3수용체 길항제를 포함하며 공포성 질환 및/또는 공간 공포증이나 강박성 신경증 질환을 치료하는데 사용되는 조성물.
  4. 공포성 질환 및/또는 공간 공포증이나 강박성 신경증 질환을 치료하는데 사용되는 약학조성물을 제조하기 위한 5-HT3수용체 길항제의 용도.
  5. 제 1 항 내지 제 4 항중 어느 한 항에 있어서, 상기 5-HT3수용체 길항제가 하기 화합물인 조성물, 용도 또는 치료방법.
    1,2,3,9-테트라히드로-9-메틸-3[(2-메틸-1H-이미다졸-1-일)메틸-4H-카르바졸-4-온; 1-메틸-인다졸-3-일 카르복실산-9-메틸-9-아자-바이시클로-[3,3,1]논-3α-일 아미드; 광학적 활성 형태 또는 라세믹 형태의 자코프라이드; 트랜스-헥사히드로-8-(3-인돌릴 카르보닐옥시)-2,6-메타노-2H-퀴놀리진-3(4H)온; 벤조[b]티엔-7-일 카르복실산 엔도-8-메틸-8-아자-바이시클로[3,2,1]옥트-3-일 에스테르; 3-(5-메틸-1H-이미다졸-4-일)-1-(1-메틸-1H-인돌-3-일)-1-프로판온; 1-메틸-인다졸-3-일 카르복실산 엔도-8-메틸-8-아자-바이시클로[3,2,1]옥트-3-일 아미드; 또는 1,2,3,9-테트라히드로-9-메틸-3-(5-메틸-1H-이미다졸-4-일)-메틸-4H-카르바졸-4-온.
  6. 제 1 항 내지 제 4 항중 어느 한항에 있어서, 상기 5-HT3수용체 길항제가 하기 화합물인 조성물, 용도 또는 치료방법; 2,3,4,5-테트라히드로-5-(페닐메틸)-2-[(5-메틸-1H-이미다졸-4-일)메틸]-1H-피리돌[4,3-b]-1-온; 5-시클로펜틸-2,3,4,5-테트라히드로-2-[(5-메틸-1H-이미다졸-4-일)메틸]-1H-피리돌[4,3-b]인돌-1-온; 2,3,4,5-테트라히드로-2-[(5-메틸-1H-이미다졸-4-일)메틸-5-프로필-1H-피리돌[4,3-b]인돌-1-온; 5-(시클로펜틸메틸)-2,3,4,5-테트라히드로-2[(5-메틸-1H-이미다졸-4-일)메틸]-1H-피리도][4,3-b]인돌-1-온; 3,4,5,6-테트라히드로-6-메틸=2-[(5-메틸-1H-이미다졸-4-일)메틸-1-아제피노[4,3-b]인돌-1-(2H)-온; 2,3,4,5-테트라히드로-N,N-디메틸-2-[(5-메틸-1H-이미다졸-4-일)메틸-1-옥소-5H-피리도[4,3-b]인돌-5-카르복시아미드; 2,3,4,5-테트라히드로-2-[(5-메틸-1H-이미다졸-4-일)메틸-5-(2-프로피닐)-1H-피리돌[4,3-b]인돌-1-온; 3-(5-메틸-1H-이미다졸-4-일)-1-(1-나프탈레닐)-1-프로판온; 1-(4-메톡시-1-나프탈레닐)-3-(5-메틸-1H-이미다졸-4-일)-1-프로판온; 1-(2-히도록시-1-나프탈레닐)-3-(5-메틸-1H-이미다졸-4-일)-1-프로판온; 1-(벤조[b]티엔-3- 일)-3-(5-메틸-1H-이미다졸-4-일)-1-프로판온; 3-(5-메틸-1H-이미다졸-4-일)-1-(1-메틸-1H-인다졸-3-일)1-프로판온; 3-(5-메틸-1H-이미다졸-4-일)(1-메틸-1H-인돌-4-일)-1-프로판온; 1,2,3,9-테트라히드로-3-((1H-이미다졸-2-일)메틸-9-메틸-4H-카르바졸론; 3-(1H-아미다졸-2-일)-1-(1-메틸-1H-인돌-3-일)-1-프로판온; 3-(5-메틸-1H-이미다졸-4-일)-1-(1,7-디메틸-1H-인돌-3-일)프로판온; 3-(5-메틸-1H-이미다졸-4-일)-1-(1-메틸-1H-인돌-3-일)-1-프로판온; 3-(5-메틸-1H-이미다졸-4-일)-1-(1,2-디메틸-1H-인돌-3-일)-1-프로판온; 2,3-디메틸-3-(5-메틸-1H-이미다졸-4-일)-1-(1-메틸-1H-인돌-3-일)-1-프로판온; N,1-디메틸-7-플루오로-N-[(5-메틸-1H-이미다졸-4-일)메틸]-1H-인돌-3-카르복시아미드; N,1-디메틸-N-[(5-메틸-1H-이미다졸-4-일)메틸]-1H-인돌-3-카르복시아미드; 1-아미노-5a,6,7,8,9,9a-헥사히드로디벤조푸란-4-(N-1-아자바이시클로-[2,2,2]옥트-3-일)카르복시아미드; 2-클로로-5a,6,7,8,9,9a-헥사히드로디벤조푸란-4-(N-1-아자바이시클로-[2,2,2]옥트-3-일)카르복시아미드; 1-아미노-2-클로로-5a,6,7,9,9a-헥사히드로디벤조푸란-4-(N-1-아자바이시클로-[2,2,2]옥트-3-일)카르복시아미드; 2-클로로-시스-5a,6,7,8,9,9a-헥사히드로디벤조푸란-4-(N-1-아자바이시클로-[2,2,2]옥트-3-일)카르복시아미드; 2-클로로-시스-5aS,6,7,8,9,9aS-헥사히드로디벤조푸란-4-(N-1-아자바이시클로-[2,2,2]옥트-3R-일)카르복시아미드; 2-클로로-시스-5aR,6,7,8,9,9aR-헥사히드로디벤조푸란-4-(N-1-아자바이시클로-[2,2,2]옥트-3S-일)카르복시아미드; 2-클로로-시스-5aR,6,7,8,9,9aR-헥사히드로디벤조푸란-4-(N-1-아자바이시클로-[2,2,2]옥트-3S-일)카르복시아미드; 2-클로로-시스-5aR,6,7,8,9,9aR-헥사히드로디벤조푸란-4-(N-1-아자바이시클로-[2,2,2]옥트-3-일)카르복시아미드; 2-클로로-시스-5aR,6,7,8,9,9aR-헥사히드로디벤조푸란-4-(N-1-아자바이시클로-[2,2,2]옥트-3R-일)카르복시아미드; 2-클로로-트랜스-5a,6,7,8,9,9a-헥사히드로디벤조푸란-4-(N-1-아자바이시클로-[2,2,2]옥트-3-일)카르복시아미드; 5,6,9,10-테트라히드로-10-[5-메틸-1H-이미다졸-4-일)메틸-4H-피리도[3,2,1-j,k]카르바졸-11-온; 3,4-디히드로-2-[5-메틸-1H-이미다졸-4-일)메틸]-1-디벤조푸라논; 3,4-디히드로-2-[5-메틸-1H-이미다졸-4-일)메틸]-1-디벤조티오페논; 6,7,8,9-테트라히드로-5-메틸-9-[(2-메틸-1H-이미다졸-1-일)메틸]-시클로헵트[b]인돌-10-온; 3,4-디히드로-2-[(5-메틸--이미다졸-4-일)메틸]-벤조푸로[3,2-c]피리딘-1(2H)-온; 3,4-디히드로-2-[5-메틸-1H-이미다졸-4-일)메틸]-[1]벤조티에노-[3,2-c]피리딘-1(2H)-온; 1,2-디히드로-3-[(5-메틸-1H-이미다졸-4-일)메틸]-4(3H)-페안트레논; 3,4-디히드로-2-[5-메틸--이미다졸-4-일)메틸]-벤즈[h]이소퀴놀린-1(2H)-온; 또는 1-(5,6-디히드로-4H-피롤로[3.2.1-i,j]퀴놀린-1-일)-3-(5-메틸-1H-이미다졸-4-일)-1-프로판온;
  7. 제 1 항 내지 제 4 항중 어느 한 항에 있어서, 상기 5-HT3수용액 길항제가 인돌-3-일 카르복실산 엔도-8-메틸-아자-바이시클로[3.2.1]옥트-3-일 에스테르인 조성물, 용도 또는 치료방법.
  8. 제 1 항 내지 제 7 항중 어느 한 항에 있어서, 상기 5-HT3수용체 길항제가 약학적 허용염 형태인 조성물, 용도 또는 치료방법.
    ※ 참고사항 : 최초 출원 내용에 의하여 공개하는 것.
KR1019900702651A 1989-04-21 1990-04-06 5-ht₃수용체 길항제의 치료용도 KR920700034A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB898909147A GB8909147D0 (en) 1989-04-21 1989-04-21 Improvements in or relating to organic compounds
GB8909147 1989-04-21
GB898916602A GB8916602D0 (en) 1989-07-20 1989-07-20 Improvements in or relating to organic compounds
GB8916602 1989-07-20
PCT/EP1990/000540 WO1990012569A1 (en) 1989-04-21 1990-04-06 Therapeutic use of 5-ht3 receptor antagonists

Publications (1)

Publication Number Publication Date
KR920700034A true KR920700034A (ko) 1992-02-19

Family

ID=26295258

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900702651A KR920700034A (ko) 1989-04-21 1990-04-06 5-ht₃수용체 길항제의 치료용도

Country Status (10)

Country Link
EP (1) EP0422154B1 (ko)
JP (1) JPH0669963B2 (ko)
KR (1) KR920700034A (ko)
AT (1) ATE97803T1 (ko)
AU (1) AU631632B2 (ko)
CA (1) CA2031214A1 (ko)
DE (1) DE69004924T2 (ko)
DK (1) DK0422154T3 (ko)
ES (1) ES2061024T3 (ko)
WO (1) WO1990012569A1 (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276050A (en) * 1989-08-01 1994-01-04 Glaxo Group Limited Medicaments
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
US5508287A (en) * 1992-02-24 1996-04-16 Merrell Pharmaceuticals Inc. 2,6-methano-2H-quinolizin derivative as 5-HT3 -receptor antagonist
JPH07507290A (ja) * 1992-05-23 1995-08-10 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 不安症の治療のための医薬
WO2011082266A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted heterocyclic compounds
US20110288115A1 (en) * 2010-05-24 2011-11-24 Avmedis Llc Treatment of vagally-mediated spectrum disorders
JP5387648B2 (ja) 2011-10-14 2014-01-15 株式会社デンソー 指針表示装置

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1365296A (en) * 1970-10-30 1974-08-29 Unilever Ltd Dentifrice compositions
EP0099194A3 (en) * 1982-07-03 1984-04-11 Beecham Group Plc Novel benzamides
NZ210940A (en) * 1984-01-25 1989-08-29 Glaxo Group Ltd 1,2,3-trihydro-3-(1h-imidazol-1-ylmethyl)-4h-carbazol-4-one derivatives and pharmaceutical compositions
DE3680123D1 (en) 1985-01-23 1991-08-14 Glaxo Group Ltd Tetrahydrocarbazolonderivate.
DE201165T1 (de) * 1985-03-14 1989-04-20 Beecham Group P.L.C., Brentford, Gb Arzneimittel zur behandlung von emesis, anxietas und "irritable bowel syndrome".
GB8518745D0 (en) 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds
GB8518658D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Medicaments
GB8518741D0 (en) 1985-07-24 1985-08-29 Glaxo Group Ltd Process
GB8518743D0 (en) 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds
EP0212398A2 (de) 1985-08-21 1987-03-04 Siemens Aktiengesellschaft Verfahren zur Erkennung von Mehrfrequenzcodesignalen mit überlagerten Störsignalen
IL80707A (en) 1985-12-23 1991-03-10 Hughes Aircraft Co Gaseous discharge device simmering circuit
DE3771376D1 (de) 1986-03-17 1991-08-22 Glaxo Group Ltd Indol-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
GB8701494D0 (en) 1987-01-23 1987-02-25 Glaxo Group Ltd Chemical compounds
GB8617994D0 (en) 1986-07-23 1986-08-28 Glaxo Group Ltd Heterocyclic compounds
EP0254584B1 (en) * 1986-07-25 1992-10-07 Beecham Group Plc Azabicyclic compounds, process for their preparation, and their pharmaceutical use
HU202108B (en) 1986-07-30 1991-02-28 Sandoz Ag Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
GB8623819D0 (en) 1986-10-03 1986-11-05 Glaxo Group Ltd Heterocyclic compounds
JP2765845B2 (ja) 1986-11-21 1998-06-18 グラクソ、グループ、リミテッド 中止症候群の予防の治療薬
GR871809B (en) 1986-11-28 1988-03-07 Glaxo Group Ltd Process for the preparation of tricyclic ketones
DE3780276T2 (de) * 1986-12-16 1993-02-25 Robins Co Inc A H Angstloesende n-(1-azabicyclo(2.2.2)oct-3-yl)benzamide und -thiobenzamide.
GB8806990D0 (en) 1988-03-23 1988-04-27 Beecham Group Plc Novel compounds
US4918080A (en) 1987-04-14 1990-04-17 Glaxo Group Limited Imidazollyl containing ketone derivatives
DE3827253A1 (de) 1987-08-20 1989-03-02 Sandoz Ag Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
NZ226032A (en) 1987-09-03 1991-12-23 Glaxo Group Ltd 2-(imidazolylmethyl)-pyrido or-azepino(4,3-b)indole-1(2h)-one derivatives; preparatory processes and pharmaceutical compositions
GB8720693D0 (en) 1987-09-03 1987-10-07 Glaxo Group Ltd Chemical compounds
GB8720805D0 (en) * 1987-09-04 1987-10-14 Naylor R J 2-alkoxy-n-(1-azabicyclo(2 2 2)oct-3-yl)benzamides & thiobenzamides
JPH01258673A (ja) 1987-10-22 1989-10-16 Glaxo Group Ltd ケトン誘導体
DE3740984A1 (de) * 1987-12-03 1989-06-15 Sandoz Ag N-oxide von heterocyclischen carbonsaeurederivaten bzw. verfahren zu deren herstellung und deren verwendung
GB8802127D0 (en) 1988-02-01 1988-03-02 Glaxo Group Ltd Chemical compounds
EP0329932B1 (en) * 1988-02-23 1995-10-18 Merrell Pharmaceuticals Inc. Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments
EP0329904A1 (en) * 1988-02-23 1989-08-30 Merrell Dow Pharmaceuticals Inc. Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of anxiety
JPH0249772A (ja) 1988-04-07 1990-02-20 Glaxo Group Ltd イミダゾール誘導体
JPH0256485A (ja) 1988-04-27 1990-02-26 Glaxo Group Ltd ラクタム誘導体
US4863921A (en) 1988-04-27 1989-09-05 Rorer Pharmaceutical Corporation Dibenzofurancarboxamides and their pharmaceutical compositions and methods
GB8812636D0 (en) 1988-05-27 1988-06-29 Glaxo Group Ltd Chemical compounds
GB8814277D0 (en) 1988-06-16 1988-07-20 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
DE69004924T2 (de) 1994-05-19
ES2061024T3 (es) 1994-12-01
CA2031214A1 (en) 1990-10-22
AU5415890A (en) 1990-11-16
EP0422154A1 (en) 1991-04-17
ATE97803T1 (de) 1993-12-15
DE69004924D1 (de) 1994-01-13
DK0422154T3 (da) 1994-03-07
WO1990012569A1 (en) 1990-11-01
AU631632B2 (en) 1992-12-03
JPH0669963B2 (ja) 1994-09-07
JPH03505881A (ja) 1991-12-19
EP0422154B1 (en) 1993-12-01

Similar Documents

Publication Publication Date Title
RU2326881C2 (ru) Конденсированные производные азолпиримидина, обладающие свойствами ингибитора фосфатидилинозитол-3-киназы (pi3k)
US5225407A (en) 5-HT3 receptor antagonists for the treatment of autism
RU2003106193A (ru) Способ лечения аллергий с использованием замещенных пиразолов
RU2007112110A (ru) Производные пирроло[2.3-с] пиридина и способы их получения
TW201041580A (en) Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
MX2008002564A (es) Uso de derivados de azabiciclohexano.
MXPA02009817A (es) Una composiciones farmaceutica para el tratamiento del dolor agudo, cronico y/o el dolor neuropatico..
SK281603B6 (sk) Použitie 5ht3 antagonistu na prípravu farmaceutickej zmesi na liečenie fibromyalgie
JP2004526699A5 (ko)
CA2594667A1 (en) Compositions and therapeutic methods utilizing a combination of a 5-ht1f inhibitor and an nsaid
KR920700034A (ko) 5-ht₃수용체 길항제의 치료용도
AP486A (en) Indole derivatives.
JP2002517393A5 (ko)
JP2004508330A5 (ko)
US20060178348A1 (en) Compositions and therapeutic methods utilizing a combination of a protein extravasation inhibitor and an NSAID
MX2007002773A (es) Derivados de aril (o heteroaril)-azolilcarbinoles (en particular, citrato de cizolirtina) para el tratamiento de la adiccion opioides.________________________________________________________ _______.
WO2002036113A1 (en) Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
JP2005503382A5 (ko)
WO2002036114A1 (en) Composition comprising serotonin receptor antagonists, 5 ht-2 and 5 ht-3
JPH0648960A (ja) 医 薬
WO2012002583A1 (en) Method for treating schizophrenia and related diseases with a combination therapy
US5530008A (en) Use of 5-HT3 receptor antagonists in treating panic disorders or obsessive compulsive disorders
JP2023065324A (ja) 抗特発性肺線維症剤
WO2001095903A1 (en) 5-ht3 receptor antagonists for treatment of disorders involving airway constriction
WO2001095902A9 (en) A composition comprising a combination of receptor agonists and antagonists

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
N231 Notification of change of applicant
E601 Decision to refuse application